Ractigen Therapeutics

Ractigen Therapeutics is a clinical-stage biopharmaceutical company specializing in RNA activation (RNAa) technology. The company develops small activating RNA (saRNA) therapeutics designed to selectively upregulate and restore the expression of endogenous genes, offering a method to address diseases previously considered undruggable. Their proprietary pipeline and drug development efforts are supported by a high-throughput discovery engine and specialized delivery platforms, including SCAD (Smart chemistry-aided delivery) for CNS targeting, LiCO (Lipid-conjugated oligonucleotide) for extrahepatic delivery, and GLORY for liver delivery. This technology aims to treat a diverse range of conditions, including oncology, neurological and neuromuscular disorders, and metabolic diseases like obesity.

By focusing on gene activation rather than gene silencing, Ractigen provides a novel therapeutic approach that can either serve as a standalone treatment or a combination therapy. The company actively pursues industrial partnerships for co-development, out-licensing, and access to its proprietary delivery systems. With a leadership team comprised of experts in RNA research and drug development, Ractigen is currently advancing several clinical-stage programs, including candidates for ALS, Duchenne muscular dystrophy, bladder cancer, and obesity. Their approach has been validated through clinical-stage trials and publications detailing the mechanism of RNAa and the efficacy of their delivery systems.